April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Ocular and Systemic Adverse Events Asociated with Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity
Author Affiliations & Notes
  • Victoria Gonzalez
    Retina, APEC, Mexico, D.F., Mexico
  • Andres Kychenthal
    Retina, Hospital Roberto del Rio, Santiago, Chile
  • Paola Dorta
    Retina, Hospital Roberto del Rio, Santiago, Chile
  • Alay Banker
    Retina, Banker, Navrangpura, Ahmedabad, India
  • Virgilio Morales-Canton
    Retina, APEC, Mexico, D.F., Mexico
  • Maria Ana Martinez-Castellanos
    Retina, APEC, Mexico, D.F., Mexico
  • Footnotes
    Commercial Relationships Victoria Gonzalez, None; Andres Kychenthal, None; Paola Dorta, None; Alay Banker, None; Virgilio Morales-Canton, None; Maria Martinez-Castellanos, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5899. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Victoria Gonzalez, Andres Kychenthal, Paola Dorta, Alay Banker, Virgilio Morales-Canton, Maria Ana Martinez-Castellanos; Ocular and Systemic Adverse Events Asociated with Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5899.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report the ocular and sytemic adverse events associated with intravitreal Bevacizumab for the treatment of Retinopathy of Prematurity

Methods: A retrospective study was performed in 262 patients (418 eyes), inyected with intravitreal Bevacizumab. Adverse events were collected and analyzed.

Results: A total of 71 local adverse events were found, including worsening of the retinal detachment, elevation of intraocular pressure, peripheral fibrous avascular membrane, vitreous hemorrage, retinal phlebitis, and cataract. Systemic adverse events included 3 deaths that apparently were not related to intravitreal bevacizumab.

Conclusions: After 7 years of follow up, intravitreal Bevacizumab appears to be safe for treatment for Retinopathy of Prematurity, with treatable ocular adverse events. Systemic abnormalities may be sequelae of prematurity itself and not related to the medication. Longer follow up is needed.

Keywords: 698 retinal development • 503 drug toxicity/drug effects • 561 injection  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×